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Abstract
Introduction: Larger populations at risk, broader use of antibiotics and longer hospital stays have impacted on the
incidence of Candida sp. bloodstream infections (CBSI).
Objective: To determine clinical and epidemiologic characteristics of patients with CBSI in two tertiary care reference
medical institutions in Mexico City.
Design: Prospective and observational laboratory-based surveillance study conducted from 07/2008 to 06/2010.
Methods: All patients with CBSI were included. Identification and antifungal susceptibility were performed using CLSI M27-
A3 standard procedures. Frequencies, Mann-Whitney U test or T test were used as needed. Risk factors were determined
with multivariable analysis and binary logistic regression analysis.
Results: CBSI represented 3.8% of nosocomial bloodstream infections. Cumulative incidence was 2.8 per 1000 discharges
(incidence rate: 0.38 per 1000 patient-days). C. albicans was the predominant species (46%), followed by C. tropicalis (26%).
C. glabrata was isolated from patients with diabetes (50%), and elderly patients. Sixty-four patients (86%) received
antifungals. Amphotericin-B deoxycholate (AmBD) was the most commonly used agent (66%). Overall mortality rate
reached 46%, and risk factors for death were APACHE II score $16 (OR= 6.94, CI95% = 2.34–20.58, p,0.0001), and liver
disease (OR = 186.11, CI95% = 7.61–4550.20, p = 0.001). Full susceptibility to fluconazole, AmBD and echinocandins among C.
albicans, C. tropicalis, and C. parapsilosis was observed.
Conclusions: The cumulative incidence rate in these centers was higher than other reports from tertiary care hospitals from
Latin America. Knowledge of local epidemiologic patterns permits the design of more specific strategies for prevention and
preemptive therapy of CBSI.
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Introduction
Candida bloodstream infections (CBSI) are the fourth cause of
nosocomial bloodstream infections in the United States [1–3], and
account for up to 10% of all bloodstream infections in hospitalized
patients [4–6]. The crude mortality rate of CBSI is about 40%
(range 5 to 70%) [1,7]. Well recognized risk factors for invasive
candidiasis are: critically ill patients in intensive care units,
diabetes mellitus, immunosuppressive states, mechanical ventila-
tion, neutropenia, recent surgical procedures and prematurity
[2,6,8].
Surveillance programs for CBSI have provided data regarding
the incidence and species distribution of Candida spp. across the
world. In Latin America a recently published paper reported an
incidence of 1.18 episodes of candidemia per 1,000 admissions,
with Candida albicans, C. tropicalis and C. parapsilosis accounting for
.80% of cases [9]. Reports of CBSI from Mexican institutions are
scarce and necessary [10,11]. The objective of this study was to
describe the incidence rate, the epidemiology of candidemia, and
to assess factors associated with death among patients with CBSI
hospitalized in two referral, tertiary care, medical institutions
located in Mexico City.
Materials and Methods
Design, Patient Selection and Data Collection
We conducted a laboratory-based survey of CBSI in two tertiary
care hospitals in Mexico, between July 2008 and June 2010: the
Salvador Zubiran National Institute of Medical Sciences and
Nutrition (INCMNSZ) and the National Cancer Institute
(INCAN). We included all hospitalized patients with at least one
positive blood culture for Candida sp. Clinical and demographic
data were collected (age, gender, co-morbidities, use of antimi-
crobials and antifungals in the 3-months period prior to CBSI,
previous use of glucocorticoids and chemotherapy within the 14
days before CBSI, neutropenia, invasive mechanical ventilation,
total parenteral nutrition, fever, septic shock, APACHE II, and
Karnosky score +/2 72 hours of the date of the incident CBSI).
Patients were followed up for 30 days after the CSBI episode or
until death. A central venous catheter (CVC) related infection was
defined as growth of .15 CFU from a 5-cm catheter tip by semi-
quantitative (roll-plate) culture and a positive blood culture [12].
Ethics statement. This study was reviewed and approved by
the local IRB’s [Comisio´n de E´tica en Investigacio´n (Commission
of Ethics in Research) at INCMNSZ and Comisio´n de Investiga-
cio´n y Bioe´tica (Commission of Research and Bioethics) at
INCAN]. Informed consent was not requested to the patients.
The IRB’s waived the need for written informed consent from the
participants, because of the observational nature of the study. The
investigators did not intervene in the standard of care. Patient
records/information was kept confidential and all identifiers were
erased prior to analysis.
Microbiological Procedures
All Candida isolates were cultured in Sabouraud cefoperazone
media, underwent germ tube testing, and identified using Ybc-
Vitek (bioMerieux, Lyon, France). After identification, antifungal
susceptibility testing was performed in all isolates for amphotericin
B deoxycholate (AmBD), 5-flucytosine, voriconazole, posacona-
zole, fluconazole, caspofungin, micafungin and anidulafungin,
following the standardized recommendations of CLSI M27-A3 for
broth microdilution method [13].
Statistical analysis
The incidence of CBSI was expressed in episodes per 1000-
discharges and per 1000 patients-day. Categorical variables were
analyzed by Pearson chi-square test or Fisher’s exact test, as
appropriate, and continuous variables by the Mann-Whitney U
test. The p value #0.05 was considered statistically significant. For
the assessment of factors associated with 30-day mortality we
compared patients who survived with those who died. Variables
with a p value #0.1 by univariate analysis were included in a
multivariate analysis using a logistic regression model. Statistical
analysis was performed using SPSS 20.0 software.
Results
Data provided in this study came from hospital-based popula-
tions from two tertiary care medical centers, which are open-
access national referral institutions. Populations attended in both
institutions are mainly complex medical and surgical problems
with variable degrees of immunosuppression (cancer, rheumatic
diseases, HIV, diabetes mellitus). During the study period, there
were 25,857 hospital discharges (24,986 from general wards and
1,295 from ICU) and 24,110 blood cultures were processed for
10,045 patients (mean 2.4 blood cultures per patient), 4,542 blood
cultures (19%) from 1,938 patients were positive. Among these
1,938 episodes, 74 proved to be cases of CBSI (3.8%). The
incidence rate of CBSI was 2.8 cases per 1000 discharges and 0.38
cases per 1,000 patients/day. The incidence in the ICU was 17
cases per 1000 discharges and 2.2 cases per 1,000 patients/day,
while in general wards the incidence was 2 cases per 1,000
discharges and 0.28 cases per 1,000 patients/day.
The mean age was 46 years (618), 29 patients (39%) had been
hospitalized within the previous three months of the CBSI episode,
and the median duration of hospitalization before the event was 16
days (0–149 days). At the occurrence of CBSI, 28 patients (38%)
were on invasive mechanical ventilation (IMV), and 57 (77%) had
received $2 types of antibiotics during the previous two weeks.
Sixty-nine patients had a CVC, which was removed, in 41 of
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them, and the tips were sent for culture; only 14 of them (34%) had
a positive culture. The other 28 CVCs were not removed. Other
clinical characteristics are described in Table 1.
C. albicans was the most common species (n = 34, 46%). Among
the non-albicans species, C. tropicalis was the most frequent (n = 19,
26%), followed by C. glabrata (n = 10, 13.5%), C. parapsilosis (n = 4,
5%), C. krusei (n = 4, 5%), C. guilliermondii (n = 2, 3%) and C.
lipolytica (n = 1, 1%). C. glabrata was isolated most frequently in
elderly patients (65613 vs 44617 years, p,0.0001) and in those
with diabetes mellitus (50 vs 15%, p= 0.024). C. tropicalis was more
commonly observed in patients with hematologic cancer and
severe neutropenia (53% vs. 20%, p= 0.01).
Nineteen patients (26%) received antifungals prior to the CBSI
(fluconazole [n = 10], AmBD [n= 8] and voriconazole [n = 1]).
They received any of these drugs for up to 12 days (median of 2 d)
because of prophylaxis, prior fungal infection or preemptive
therapy. Sixty-four patients (86%) received antifungal therapy to
treat the episode of CBSI, AmBD was the most commonly used
agent (n = 42, 66%), followed by echinocandins (n = 13, 20%), and
fluconazole (n = 8, 13%). One patient received a combination of
fluconazole and AmBD (1%). Twenty-nine of the 64 patients who
received therapy died (45.3%), 17 of them within the first 7 days of
antifungal treatment. Ten patients did not receive antifungal
treatment, five died the day that blood samples were drawn, two
Table 1. Clinical and demographic characteristics of patients who survived or died within 30 days after candidemia.
Characteristics Alive (n =40) Dead (n =34) All (n = 74) P
Mean age (Years) 6 s.d.a 48617 45619 46618 0.26
Cancer – n (%) 24 (60) 18 (53) 42 (56.8) 0.54
Liver disease 2 (5) 7 (20.6) 9 (12) 0.07
Acute kidney injury 15 (37) 21 (62) 36 (48) 0.06
Chronic kidney disease 5 (12.5) 10 (29.4) 15 (20.3) 0.088
All types of transplant 1 (2.5) 5 (14.7) 6 (8.1) 0.08
Chemotherapy 9 (22.5) 12 (35.3) 21(28) 0.32
Surgery 24 (60) 12 (35) 36 (49) 0.03
Cardiovascular disease 11 (28) 14 (41) 25 (34) 0.23
Diabetes mellitus 8 (20) 7 (21) 15 (20) 1
Autoimmune disease 7 (18) 7 (21) 14 (19) 0.77
Prior use of glucocorticoids 11 (27.5) 19 (55.9) 30 (40.5) 0.018
Neutropenia 9 (22.5) 12 (35.3) 21 (28) 0.3
TPNb 10 (25) 9 (26.5) 19 (25.7) 0.88
Mechanical ventilation 8 (20) 20 (58.8) 28 (37.8) 0.001
Antibiotics (more than 4 types)c 23 (57.5) 25 (73.5) 48 (64.9) 0.22
Fever 37 (92.5) 33 (97) 70 (94.6) 0.62
Severe sepsis 9 (22.5) 23 (67.6) 32 (43) ,0.0001
Septic shock 2 (5) 17 (50) 19 (25.7) ,0.0001
Candida deep infection 4 (10) 8 (23.5) 12 (16.2) 0.2
APACHE II Score 12 (3–25) 25 (12–36) 18 (3–36) , 0.0001
Delayed start of treatment (days) 1 (2–6) 1 (0–8) 1 (2–8) 0.79
Duration of antifungal therapy 15 (1–55) 6 (1–41) 13 (1–55) 0.004
Untreated patients 3 (7.5) 7 (20) 10 (13.5) 0.17
as.d., Standard deviation; bTPN, Total parenteral nutrition; cfamilies of antibiotics were: broad–spectrum penicillins, broad-spectrum cephalosporins, carbapenems,
aminoglycosides, glycopeptides, linezolid or quinolones.
doi:10.1371/journal.pone.0097325.t001
Table 2. Risk factors for death: Cox proportional-hazards regression model.
Characteristic Univariate HR (IC 95%) P Multivariate* HR (IC 95%) P
APACHE II Scorea 6.94 (2.34–20.58) ,0.0001 12.13 (1.89–77.5) 0.008
Liver disease 11.25 (1.32–95.37) 0.026 186.11 (7.61–4550.20) 0.001
Invasive mechanical ventilation 2.40 (0.91–6.29) 0.074
CVC removal b 0.26 (0.08–0.81) 0.020
Prior use of steroid 0.42 (0.16–1.08) 0.073
a$16 points; b CVC, Central venous catheter.
doi:10.1371/journal.pone.0097325.t002
Surveillance of Candidemia in National Institutes of Health in Mexico
PLOS ONE | www.plosone.org 3 May 2014 | Volume 9 | Issue 5 | e97325
died within the next three days of isolation, and the other three
asked for voluntary discharge.
Overall, 28 of the 74 patients (38%) died within 15 days after
diagnosis of CBSI and 34 (46%) within 30 days. There were no
differences in mortality between the different species of Candida.
Likewise, no differences in mortality rates were observed among
ICU and non-ICU patients or types of antifungal therapy. By
contrast, variables associated with higher mortality rates by
Table 3. Activity of antifungal agents among Candida species isolated during this study using CLSI M27-A3 BMD methods
(n = 67)a,,b.
Species (No. tested) Antifungal Agent MIC (mcg/ml) % Resistance
Range MIC50 MIC90
C. albicans (n = 32) Amphotericin 0.125–2 0.5 1
Anidulafungin c 0.015–0.06 0.015 0.03 0
Caspofungin c 0.015–0.06 0.03 0.06 0
Micafungin c 0.015–0.03 0.015 0.015 0
Fluconazole 0.125–1 0.25 1 0
Posaconazole 0.03–0.06 0.03 0.03 0
Voriconazole 0.03–1 0.03 0.03 0
Flucytosine 0.25–4 0.125 0.5 0
C. tropicalis (n = 18) Amphotericin 0.25–2 0.5 1
Anidulafungin c 0.015–0.06 0.015 0.03 0
Caspofungin c 0.015–0.25 0.06 0.125 0
Micafungin c 0.015–0.03 0.015 0.03 0
Fluconazole 0.125–2 0.25 1 0
Posaconazole 0.03–0.06 0.03 0.03 0
Voriconazole 0.03–0.25 0.03 0.06 0
Flucytosine 0.125–64 0.125 0.5 0
C. glabrata (n = 9) d Amphotericin 0.125–2 0.5 1
Anidulafungin c 0.015–0.06 0.015 0.03 0
Caspofungin c 0.06–0.125 0.125 0.125 0
Micafungin c 0.015–0.06 0.015 0.015 0
Fluconazole 1–64 4 16 11
Posaconazole 0.06–2 0.25 0.25 11
Voriconazole 0.06–4 0.25 0.25 11
Flucytosine 0.125–0.5 0.125 0.25 0
C. parapsilosis (n = 4) Amphotericin 0.25–0.5 0.5 0.5
Anidulafungin c 0.06–1 0.5 1 0
Caspofungin c 0.25 0.25 0.25 0
Micafungin c 0.25–1 0.5 1 0
Fluconazole 0.125–0.5 0.25 0.5 0
Posaconazole 0.03 0.03 0.03 0
Voriconazole 0.03 0.03 0.03 0
Flucytosine 0.125 0.125 0.125 0
C. krusei (n = 2) Amphotericin 1–2 1 2
Anidulafungin c 0.06–0.125 0.06 0.125 0
Caspofungin c 0.25–0.5 0.25 0.5 0
Micafungin c 0.06 0.06 0.06 0
Fluconazole 16–32 16 32
Posaconazole 0.125 0.125 0.125 0
Voriconazole 0.25 0.25 0.25 0
Flucytosine 16–32 16 32 100
a. MICs determined based on CLSI M27-A3; b. The susceptibilities of 3 species are not shown (2-C. guilliermondii, and 1-C. lipolytica); c. Non-resistant isolates were
identified for echinocandins; d. One C. glabrata isolate showed dose-dependent susceptibility (MIC = 16 mcg/ml) and susceptibility to voriconazole and posaconazole.
One C. glabrata isolate was resistant to fluconazole (MIC = 64 mcg/ml), voriconazole (MIC = 4 mcg/ml) and posaconazole (MIC = 2 mcg/ml).
doi:10.1371/journal.pone.0097325.t003
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univariate analysis were: prior use of glucocorticoids, liver disease,
removal of CVC, IMV, low Karnofsky score, severe sepsis, septic
shock, and APACHE II score $16 (Table 1).
Prognostic factors associated with 30-day mortality assessed by
univariate and multivariate analysis are shown in Table 2. In
multivariate analysis, independent variables associated with death
were liver disease, and APACHE II score $16. Removal of CVC
at anytime was associated with a favorable outcome in the
univariate analysis, but it was not confirmed in the multivariate
analysis. (Table 2).
Antifungal susceptibility data of 68 isolates were available
(Table 3). All isolates were susceptible to echinocandins. For
micafungin and anidulafungin, the MIC90 value was #0.06 mcg/
ml, and for caspofungin was #0.25 mcg/ml. The MIC90 of
voriconazole and posaconazole for all species was #0.125 mcg/
ml. All isolates of C. albicans, C. parapsilosis and C. tropicalis were
susceptible to fluconazole using CLSI M27-A3 guidelines. The
MIC90 of fluconazole for C. albicans and C. tropicalis was 1 mcg/
ml, and for C. parapsilosis 0.5 mcg/ml. Two of nine C. glabrata
isolates tested, showed high MICs values for fluconazole, one
showed resistance to all azoles, and the other one exhibited a high
MIC value only for fluconazole. The two isolates of C. guilliermondii
were susceptible to fluconazole (2 and 4 mcg/ml), and one C.
lipolytica showed an MIC value of 2 mcg/mL for fluconazole
(Table 3).
Discussion
This is the first surveillance study of CBSI performed in Mexico
in which incidence rates, species distribution, antifungal therapy
and predictors of outcome were analyzed. We observed a high
incidence of CBSI. Common risk factors identified previously were
confirmed. A high crude mortality rate was observed which was
associated with high APACHE II scores and other severe
conditions. All clinical isolates included in this report were fully
susceptible to echinocandins.
The cumulated incidence (2.8 cases per 1000 discharges) and
incidence rate (0.38 cases per 1000 patient-days) reported in this
study are higher than the ones from other recent reports. Studies
done in other tertiary care hospitals in the European Community
and the USA have shown cumulated incidence between 0.17 and
1 case per 1000 discharges [14]. Nucci et al. recently reported
lower incidence rates (1.18 cases per 1,000 discharges and 0.23
cases per 1,000 patients-day) in 21 tertiary care hospitals in 7
countries in South and Central America [9].
The incidence rate in this study was 0.38 cases per 1000 patient-
days, which is similar to the incidence rate reported in the
nationwide sentinel surveillance study done in Brazil (0.37 cases
per 1000 patients/day) during last decade [5,7]. In Switzerland,
after a 10-year surveillance in tertiary care centers, the overall
incidence rate was 0.049 cases per 1,000 patient-days [14].
Including the findings of this study, the incidence rate seen in
tertiary care hospitals in Latin America is almost 100 times greater
than those seen in the European Community. In summary, we
observed a higher cumulated incidence, and a higher incidence
rate than in other regions, including Latin American countries.
C. albicans continues to be the most common species causing
CBSI worldwide (»40% to 60% of cases) and it was the main agent
(46%) in this study as well, even though it has been well
documented that since the introduction of second-generation
azoles there has been a steady increase in the isolation of non-
albicans species [15].
In our study, C. tropicalis was the most common non-albicans
agent (26%) followed by C. glabrata (13.5%), whereas C. parapsilosis
was an uncommon pathogen (5%). In the USA, the most common
species, after C. albicans, has been C. glabrata (10 to 21%) [1,16]. C.
parapsilosis is one of the most common isolates in Latin America
(20%), in contrast, C. glabrata has been uncommon in Latin
American reports (,6%) [5,16].
Different distribution patterns could be explained by three main
factors, the intensity of use of fluconazole for prophylaxis, the age
of the population at risk, and infection control practices.
Prophylaxis with fluconazole has been associated with a decrease
in the rate of CBSI among patients with hematologic malignan-
cies; however, its use favors the selection of resistant species such as
C. glabrata [8,17,18]. In the USA, prophylaxis with fluconazole is
used more extensively than in Latin America, which may account
for the difference in patterns. The second point has been recently
raised since C. parapsilosis is the principal mucosal colonizer in the
newborn population, whereas C. glabrata is more common in
elderly patients [1,19]. Our study included adult population (mean
age 46618 years), whereas most of the Latin American studies
have included newborn, pediatric, and adult populations
[1,10,19]. Finally, there are strong differences in the infection
control practices in the world and C. parapsilosis has been
associated with outbreaks of CVC related CBSI. Therefore, high
rates of C. parapsilosis recovery could indicate careless CVC
handling in many settings [10,15,20,21]. The low prevalence of C.
parapsilosis among the populations included in this study confirms
the strict policy of CVC care, as seen in previous reports from both
participant institutions [22,23].
Liver disease and APACHE II score $16 were the major risk
factors of mortality. CBSI has been associated with the develop-
ment of septic shock in 23% of the cases [4,24,25]. Increased
mortality rates have been noticed in patients with CBSI who did
not receive empirical/preemptive therapy within the first 24 hrs,
mainly in patients with septic shock [4,26,27]. We observed a high
mortality rate within the first 7 days, which may confirm indirectly
the need of early and preemptive treatment in critically ill patients,
as reported elsewhere in hematopoietic stem cell transplant
recipients [28,29]. The majority of those who received treatment
for less than 6 days were critically ill and died soon after CBSI
diagnosis, which could have limited the efficacy of antifungals.In
our study, not removing the CVC was not associated with a poorer
outcome by multivariate analysis. However, our number of
patients is small and therefore, a stronger recommendation
regarding CVC management is not warranted [9,30,31].
Most of the clinical isolates were susceptible to all antifungal
agents. In Latin America, AmBD and fluconazole are broadly
used, with less extended use of echinocandins. The less extended
use of echinocandins is mostly due to lack of access and high prices
to these agents [30,32]. International studies have reported
resistance to fluconazole in less than 1.5% of C. albicans, C.
tropicalis and C. parapsilosis isolates [33]. In this study, C. albicans, C.
tropicalis and C. parapsilosis were 100% susceptible to all kind of
antifungal agents. However, potential resistant species were
identified in 21% of our study population (C. glabrata 10, C. krusei
4, C. guilliermondii 2 and C. lipolytica 1). The main resistant species,
reported worldwide, is C. glabrata, which was not as common as C.
albicans, and C. tropicalis in our study. Usually, C. glabrata is
associated with approximately 30% of resistance to fluconazole
[33,34]; in this study, the rate of resistance of C. glabrata was lower
than prior reports.
Despite the susceptibility patterns described in our report,
continuous surveillance programs are needed in order to identify
possible changes in the species distribution and antifungal
susceptibility patterns of yeasts, particularly in Latin American
hospitals [21,33].
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This study has several limitations such as the low number of
cases, the restricted geographic region where the study was
performed, and the type and number of institutions included. Both
institutions are open-access tertiary care referral centers, which
attend only adult patients. These characteristics may limit the
generalization of our findings to other geographic zones in Mexico
and Latin America, and also, cannot be applied to other clinical
settings, such as pediatric and newborn medical units. Finally, the
number of isolates included could underestimate the antifungal
resistance rate among the population studied.
In conclusion, in this study we described a higher incidence of
CBSI than that of others countries, as well as differences in the
epidemiology of CBSI in comparison with previous reports. The
reasons of these differences are not clear. Nevertheless, longer and
more comprehensive surveillance programs will allow us to have a
better understanding of the epidemiology and susceptibility
patterns of CBSI in limited-resource countries.
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